FY2024 EPS Estimates for electroCore Decreased by Analyst

electroCore, Inc. (NASDAQ:ECOR) – Equities researchers at Brookline Capital Management dropped their FY2024 earnings per share (EPS) estimates for shares of electroCore in a research report issued to clients and investors on Thursday, November 14th. Brookline Capital Management analyst T. Bussian now forecasts that the company will post earnings of ($1.40) per share for the year, down from their previous forecast of ($1.03). The consensus estimate for electroCore’s current full-year earnings is ($1.44) per share. Brookline Capital Management also issued estimates for electroCore’s Q4 2024 earnings at ($0.33) EPS.

electroCore Stock Performance

Shares of NASDAQ ECOR opened at $10.94 on Monday. electroCore has a 52 week low of $5.02 and a 52 week high of $14.20. The stock’s fifty day moving average is $8.89 and its 200 day moving average is $7.23. The stock has a market capitalization of $71.66 million, a P/E ratio of -5.98 and a beta of 0.56.

Institutional Investors Weigh In On electroCore

A number of large investors have recently modified their holdings of ECOR. International Assets Investment Management LLC lifted its position in shares of electroCore by 689.1% during the 3rd quarter. International Assets Investment Management LLC now owns 535,146 shares of the company’s stock worth $3,864,000 after buying an additional 467,326 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of electroCore by 3.4% in the second quarter. Renaissance Technologies LLC now owns 68,786 shares of the company’s stock worth $442,000 after acquiring an additional 2,270 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of electroCore by 10.3% in the 3rd quarter. Geode Capital Management LLC now owns 63,485 shares of the company’s stock valued at $458,000 after purchasing an additional 5,951 shares in the last quarter. Finally, HighTower Advisors LLC bought a new stake in shares of electroCore during the 3rd quarter valued at approximately $255,000. Institutional investors and hedge funds own 26.74% of the company’s stock.

About electroCore

electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.